FDA accepts NDA resubmission for PEDMARK™

OHSU startup Fennec Pharmaceuticals, Inc. has resubmitted its New Drug Application for approval of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of ototoxicity induced by cisplatin.
chemotherapy in patients one month to < 18 years of age with localized, non-metastatic, solid tumors. This work was pioneered by Edward Neuwelt, M.D., professor of neurology and neurological surgery in the OHSU School of Medicine and director of the Blood-Brain Barrier Program.

BIP awards three drug discovery innovators for 2021

Now in its ninth year, OCTRI’s Biomedical Innovation Program, a collaboration with OHSU Technology Transfer and OHSU Collaborations & Entrepreneurship, awards funding, project management, and mentorship to facilitate the development of innovative technologies at OHSU and accelerate their translation to the marketplace.

Three OHSU investigators will be funded in the program’s drug discovery track this year. This category of funding supports drug discovery platforms and early-stage therapeutic technology projects, including validation of drug targets and development of small molecules, antibodies, vaccines or biologics.

Congratulations to the following investigators:

**Nabil J. Alkayed, M.D., Ph.D.,** professor of Anesthesiology and Perioperative Medicine; director of research, Knight Cardiovascular Institute
Abstract: *A Novel Therapeutic Target in Subarachnoid Hemorrhage (SAH)*

**Mallesh Pandrala, Ph.D.,** assistant staff scientist, Department of Cell, Developmental & Cancer Biology, Center for experimental therapeutics, Knight Cancer institute, OHSU
Abstract: *Development of a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia with Improved Safety*

**Sanjay V. Malhotra, Ph.D.,** FRSC, professor & endowed chair in cancer research, Department of Cell Development & Cancer Biology, Director, Center for Experimental Therapeutics, Knight Cancer Institute
Co-Investigators: Alexander Honkala, Marie Foss, Ph.D.
Abstract: *Addressing Paclitaxel Resistance and Disease Progression in Ovarian Cancer with Small Molecule YBX1 Inhibitors*

Award funding is provided by OCTRI and the OHSU Foundation via the University Venture Development Fund.

**OHSU Innovation and Commercialization internship program seeking applications**

Are you interested in a career in technology transfer, business development, or patent law? The **OHSU Innovation and Commercialization internship program** provides real-world experience with innovation development and the transition of technology from laboratory to market. Volunteer interns may be eligible for a monthly stipend or academic credit, depending on their role and affiliation. The program begins in October 2021. Applications are due Aug. 8, 2021. **Apply today.**

**New gene therapy strategy for liver repopulation**

Researchers at OHSU, led by **Markus Grompe, M.D.**, professor of pediatrics and molecular and medical genetics in the OHSU School of Medicine, **have developed** an innovative gene therapy strategy to overcome some of the current major limitations of rAAV and lentivirus liver-directed gene therapy. This therapy is intended for treatment of diseases such as a rare inherited disorder phenylketonuria, also called PKU, and other disorders that require intervention in early childhood.
Inherent Targeting shares their SBIR funding success story

The OHSU startup, Inherent Targeting, received a $2.25 million NIH SBIR Fast Track Phase I/II grant to support the development of nerve-targeted fluorescent contrast agents. The CEO of Inherent Targeting, Connor Barth, Ph.D., talks about launching a company as an OHSU scientific co-founder and receiving the SBIR grant in an interview with ScienceDocs.

NIH releases vision for new scientific entity, Advanced Research Agency for Health

Leaders of the White House Office of Science and Technology Policy, the National Institutes of Health, and other organizations have proposed a new scientific agency at the NIH, the Advanced Research Agency for Health (ARPA-H), to champion innovative ideas in health and medicine.

ARPA-H would focus on solving practical problems that foster breakthroughs to serve patients equitably. The vision for this agency was shared in a recent article in Science.

OHSU's STAR Lab launches medical training into augmented reality

OHSU medical students, Ashraf Samhan and Stephanie MacDonald, won the 2021 OHSU Student Innovator Challenge, which comes with a $2,500 grant and mentoring to advance their idea to prototype. It also brings the opportunity to compete for up to $30,000 in cash prizes against 17 other collegiate teams at the Invent Oregon state finals. Their project is an augmented reality technology designed to enhance medical student training on surgical rotations, with the goal of overcoming disparities in surgical training. They are members of the Surgical Telehealth Analytics and Research Laboratory (STAR Lab) led by Vahagn Nikolian, M.D. Bright futures await these med students!
Educational webinar available for startup companies

Take advantage of startup-related educational webinars, podcasts and articles directed to a vast array of topics from the viewpoint of investors and entrepreneurs. OHSU has a relationship with Osage University Partners (OUP) - a venture capital firm that invests in university startup companies - that brings these educational assets to you at no charge. They also host topical discussions on university startup practices and programs. Check out their website to find out more.

OHSU startup release documentary

A 30-minute documentary by United in Heart, an OHSU startup and 501(c)(3) nonprofit, is now available on Amazon Prime. United in Heart focuses on food forests and diet change as ways to address the impact of climate instability. Former CNN anchorwoman Jane Velez-Mitchell declared, “This short documentary explains it all. It must be seen everywhere!” “United in Heart: Hunger & Climate Solutions” is available to rent. No charge for Amazon Prime subscribers.

FUNDING OPPORTUNITIES

Multidisciplinary || OHSU School of Medicine IDEA Seed Grants for Innovation, Development & Exploration for research Advancement

What: Supports investigators who need to work with an OHSU core or with the Pacific Northwest National Laboratory (PNNL) to develop preliminary data for an application for extramural research support

Who should apply: School of Medicine faculty in the professorial series who have not received this award within the last year

Award: Up to $5,000/one year

Deadline: Applications accepted anytime

Apply through the CAP
**Multidisciplinary OCTRI Mobile Apps for Clinical Studies (MACS)**

**What:** Funding to leverage new the REDCap functionality MyCap to create mobile apps that allow clinical study participants to report outcomes/data via a smartphone; the program aims to help fill the pipeline for BIP Digital Health by allowing PIs to conduct preliminary research and obtain user experience data

**Who should apply:** PIs who meet OHSU Principal Investigator requirements and want to create a mobile app for clinical or commercial purposes

**Award:** Up to $5,000/typically one year

**Deadline:** Rolling; application will close when funding for the fiscal year is exhausted

Submit your project intake form through REDCap

---

**Multidisciplinary OCTRI Human Investigations Program**

**What:** A series of courses to enhance your clinical and translational research career

**Who should apply:** Faculty and clinical and postdoctoral fellows employed at OHSU, VA Portland Health Care System or other Northwest healthcare systems and graduate students enrolled in SOD, SOM, SON or SOPH

**Degrees offered:** Certificate in Human Investigations or a Master of Clinical Research

**Deadline:** July 15, 2021

---

**Cancer OHSU Knight Cancer Institute and AstraZeneca Partner of Choice**

**What:** Partnership between Knight Cancer Institute and AstraZeneca that solicits proposals using the KCI’s site-specific capabilities to advance understanding of disease biology and resistance mechanisms; see this OHSU Now post for more information and materials to assist in drafting a proposal

**Who should apply:** KCI researchers

**Award:** Contact Dan Coleman, Alliance Manager for the AstraZeneca Partner of Choice Program at OHSU, for budget questions

**Deadline:** Proposals due to AstraZeneca June 30, 2021; if interested in drafting a proposal, contact Dan Coleman

---

**TECHNOLOGIES AVAILABLE FOR LICENSING**

**OHSU #2333** - Glaucoma tube implant with modulated flow
**OHSU #2414** - MicroRNA inhibitors to enhance radiotherapy efficacy

**OHSU #2533** - Adaptive exercise-enabled model-predictive-control artificial pancreas control algorithm

**OHSU #1967/2750** - Compositions for treatment of neurological and oxidative stress disorders

---

**NEWLY LICENSED OR OPTIONED OHSU TECHNOLOGIES**

**OHSU # 1771** - Materials from the BioLibrary

**OHSU # 2700** - A strong mini-promoter for AAV (Inventors Sunghee Chai, Ph.D., and Markus Grompe, M.D.)

**OHSU # 2808** - Methods for producing mouse monoclonal antibodies against viral capsids and products generated thereby (Inventors Kei Adachi, Ph.D., Hiroyuki Nakai, M.D., Ph.D., and Helen Rappe Baggett)

**OHSU # 2904** - Composition and methods for delivery of AAV (Inventors Kei Adachi, Ph.D., and Hiroyuki Nakai, M.D., Ph.D.)

**OHSU # 2905** - Thin large-diameter optics foldable intraocular lens with gradient refractive index (Inventor David Huang, M.D., Ph.D.)

**OHSU # 2966** - A custom 185 point grid using the GATE examination strategy and Goldmann stimulus size V that is specifically designed for subjects with Retinitis Pigmentosa (RP) and similar retinal dystrophies and for use in 3-D Hill of Vision modeling and volumetric measurements (Inventor Richard Weleber, M.D.)

**OHSU # 2994** - A strong mini-promoter for AAV delivered gene expression (Inventors Sunghee Chai and Markus Grompe, M.D.)

---

**U.S. PATENTS ISSUED**
**Patent # 11,049,247** - Methods, systems, and apparatuses for quantitative analysis of heterogeneous biomarker distribution

**Patent # 11,028,444** - Survival predictor for diffuse large B cell lymphoma

**Patent # 11,028,397** - 5'-triphosphate oligoribonucleotides

---

**Researchers in New Industry-Funded Research Projects**

- **Stephen Spurgeon, M.D.** - MALT1 inhibition in non-Hodgkin's lymphoma
- **Monika Davare, Ph.D.** - Investigating the effectiveness of NUV-250 in diverse ROS1 fusion proteins and ROS1 kinase domain resistance mutations
- **Evan Lind, Ph.D.** - Recognition of WT1 expressing AML blasts by TCR transgenic cell
- **Rebecca Silbermann, M.D., M.M.S.** - Optimal sequencing determination for relapsed multiple myeloma
- **Martina Mancini, Ph.D.** - Study by OHSU’s Balance Disorders Laboratory

---

**Featured Event**

**Lunch and Learn: Patent process for bioscience startups**

As an innovator and startup, do you have questions about the patent process? Hear from two U.S. Patent and Trademark Office (USPTO) supervisory patent examiners as they provide an overview and answer questions about the patent process with particular insights for applicants in the bioscience technologies.

Date: Wednesday, July 14, 2021. Noon - 1:30 p.m.

Speakers: USPTO Supervisory Patent Examiners Jim Alstrum-Acevedo (TC 1600) and Pascal Bui-Pho (TC 3700)
Topics include:

- Navigating the USPTO patent process with an emphasis on bioscience technologies.
- Tips and common mistakes on patent applications.
- Understanding the risks of early disclosure.
- Resources and assistance available through the USPTO.

Register today.

UPCOMING EVENTS

JULY 8
Accelerate Biotech + Digital Health Happy Hour

JULY 13
AngelMD Healthcare Impact Investing Summit

JULY 19-23
2021 National SBIR Week

JULY 22
What product does the healthcare industry sell?

JULY 29
Kauffman Foundation Entrepreneurship Forum
Inclusive prosperity through innovation and entrepreneurship

SEPT 1
TIE Women Pitch Competition

SPONSORS

We welcome and appreciate the collaborative nature of organizations that want to be a part of the ongoing innovative and entrepreneurial efforts at
OHSU. Thank you to our sponsors!

Questions? Contact us at techmgmt@ohsu.edu.

This monthly publication is created in collaboration with OHSU Technology Transfer, OHSU Collaborations and Entrepreneurship, and the Oregon Clinical and Translational Research Institute.

©2021 OHSU
3181 S.W. Sam Jackson Park Rd. Portland, OR, 97239, US
Unsubscribe